Terrapinn's World Influenza Congress Europe 2009, held in Brussels, included topics covering new developments in the field of influenza vaccination. This conference report highlights selected presentations on the use of novel technologies for developing vaccines for influenza. Investigational vaccines discussed include Multimeric-001 (BiondVax Pharmaceuticals Ltd), NB-1008 (NanoBio Corp) and an influenza vaccine containing the CAF-01 adjuvant (Statens Serum Institut).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Terrapinn's world influenza congress Europe 2009. Part 2.
IDrugs
February 2010
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
Terrapinn's World Influenza Congress Europe 2009, held in Brussels, included topics covering new developments in the field of influenza vaccination. This conference report highlights selected presentations on the use of novel technologies for developing vaccines for influenza. Investigational vaccines discussed include Multimeric-001 (BiondVax Pharmaceuticals Ltd), NB-1008 (NanoBio Corp) and an influenza vaccine containing the CAF-01 adjuvant (Statens Serum Institut).
View Article and Find Full Text PDFTerrapinn's world influenza congress Europe 2009. Part 1.
IDrugs
February 2010
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
Terrapinn's World Influenza Congress Europe 2009, held in Brussels, included discussions of the current status of influenza worldwide. This conference report highlights selected presentations on the response to the H1N1 influenza pandemic, future strategies for combating pandemic influenza, and the role of novel vaccine technology in the pandemic response. Investigational vaccines discussed include M2del11HAavir H1N1 and M2del11HAavir H5N1 (FluGen Inc).
View Article and Find Full Text PDFWorld Vaccine Congress Lyon - Terrapinn's 11th Annual Congress.
IDrugs
December 2009
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.
The 11th Annual World Vaccine Congress, held in Lyon, included topics covering new therapeutic developments in the field of vaccines. This conference report highlights selected presentations on the role of big pharma in vaccine development, the future direction of vaccine R&D, influenza preparedness in Europe, and vaccines for Staphylococcus aureus, CMV and cancer. Investigational drugs discussed include an H5N1 influenza vaccine program from Baxter International Inc/DynPort Vaccine Co LLC, FP-01 (Immune Targeting Systems Ltd), FluGEM (Mucosis BV), a nonstructural protein-1-altered live-attenuated influenza vaccine candidate from Vivaldi Biosciences Inc, PentaStaph (GlaxoSmithKline plc) and StaphVAX (Nabi Biopharmaceuticals), VCL-CB01 (Vical Inc) and astuprotimut-r (GlaxoSmithKline).
View Article and Find Full Text PDFWorld Vaccine Congress Lyon 2008--Terrapinn's tenth annual congress.
IDrugs
December 2008
Thomas Reuters, London, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!